Jianli Dong
Jianli Dong, MSc, MD, PhD
Professor and Director
  • :(409) 772-4866
  • :(409) 772-5683

Department of Pathology
University of Texas Medical Branch




M.D., The First Military Medical University
Guangzhou, Guangdong, China
1984-1985 Intern in Medicine,
Pearl River Hospital (Affiliate Hospital of The First Military Medical University)
Guangzhou, Guangdong, China
1985-1987 Resident, Internal Medicine/Infectious Diseases/Hepatology
Beijing Institute of Infectious Diseases
302 Hospital
Beijing, China
1987-1989 M.Sc. (incomplete due to relocating to Canada)
Academy of Military Medical Sciences
Beijing, China
1990-1992 M.Sc., Medical Sciences, Institute of Medical Sciences
University of Toronto
Toronto, Ontario, Canada
1992-1998 Ph.D., Department of Molecular and Medical Genetics
University of Toronto
Toronto, Ontario, Canada
1998-1999 Research Fellow, Department of Genetics
Yale University School of Medicine
New Haven, Connecticut
1999-2001 Clinical Fellow, American Board of Medical Genetics Program, Department of Human Genetics
Mount Sinai School of Medicine
New York, New York



Dr. Jianli Dong received her medical degree from Guangzhou China and worked as an internal medicine physician for several years in Beijing. She then received her PhD from University of Toronto, Canada, followed by a research postdoc at Yale University and a clinical fellowship in molecular genetics at Mount Sinai School of Medicine in New York City. Currently she is Professor and Director of Molecular Diagnostics Division in the Pathology Department at the University of Texas Medical Branch.

Research Interest

She has focused her research on two areas: RAS-RAF-MEK-ERK and p16INK4A-CDK4/6-RB pathways in cancer biology, and research and development of molecular assays for clinical applications.

Professional Activities:

1989-1990 attending Physician Beijing Institute of Infectious Diseases 302 Hospital
Beijing, China
2001-2005 Assistant Professor
Department of Pathology
Mount Sinai School of Medicine
New York, NY
2004-2005 Director
Molecular Diagnostics Laboratory
New York Blood Center
New York, NY
2005-present Director Molecular Diagnostics Division
Department of Pathology
University of Texas Medical Branch
Galveston, TX
2005-2009 Assistant Professor (Tenure Track)
Department of Pathology
University of Texas Medical Branch
Galveston, TX
2006-present Investigator
Sealy Center for Cancer Cell Biology (SCCCB)
University of Texas Medical Branch
Galveston, TX
2006-2009 Adjunct Assistant Professor
School of Health Sciences
University of Texas MD Anderson Cancer Center
Houston, TX
2009-2014 Associate Professor (with Tenure)
Department of Pathology
University of Texas Medical Branch
Galveston, TX



  1. Dong, J.; Asa, S.L.; Drucker, D.J. Islet cell and extrapancreatic expression of the LIM domain homeobox gene isl-1. Mol. Endocrinol. 5: 1633-1641; 1991.
  2. Dong, J.; Strome, R.; Hung, L.H.; Krause, H.M. A phosphorylation site in the Ftz homeodomain is required for activity. EMBO J. 17: 2308-2318; 1998.
  3. Drean, B.S.; Nasiadka, A.; Dong, J.; Krause, H.M. Dynamic changes in the functions of odd-skipped during early Drosophila embryogenesis. Development. 125: 4851-4861; 1998.
  4. Dong, J.; Krause, H.M. Tissue-specific requirements for a phosphorylation site in the Fushi tarazu homeodomain. Dev. Genes Evol. 209: 427-431; 1999.
  5. Dong, J.; Gailani, M.R.; Pomeroy, S.L.; Reardon, D.; Bale, A.E. Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum Mutat. 16: 89-90; 2000.
  6. Dong, J.; Katz, D.R.; Eng, C.M.; Kornreich, R.; Desnick, R.J. Non-radioactive detection of the common connexin 26 167delT and 35delG mutations and frequencies among Ashkenazi Jews. Mol. Genet Metab. 73: 160-163; 2001.
  7. Edelmann, L.; Dong, J.; Desnick, R.J.; Kornreich, R. Carrier screening for mucolipidosis type IV in the American Ashkenazi Jewish population. Am J Hum Genet. 70: 1023-1027; 2002.
  8. Dong, J.; Edelman, L.; Bajwa, A.M.; Kornreich, R.; Desnick, R.J. Familial dysautonomia: detection of the IKAPIVS20+6T®C and R696P mutations and frequencies among Ashkenazi Jews. Am J Med Genet. 110: 253-257; 2002.
  9. Krasilnikov, M.; Ivanov, V.N.; Dong, J.; Ronai, Z. ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications regarding sensitization of melanoma to apoptosis. Oncogene. 22: 4092-4101; 2003. PMID: 12821943.
  10. Dong, J.; Phelps, R.G.; Qiao, R.; Yao, S.; Benard, O.; Ronai, Z.; Aaronson, S.A. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 63: 3883-3885; 2003. PMID: 12873977.
  11. Manfredi, J.J.; Dong, J.; Liu, W.J.; Resnick-Silverman, L.; Qiao, R.; Chahinian, P.; Saric, M.; Gibbs, A.R.; Phillips, J.I.; Murray, J.; Axten, C.W.; Nolan, R.P.; Aaronson, S.A. Evidence against a role for SV40 in human mesothelioma. Cancer Res. 65: 2602-2609; 2005. PMID: 15805256.
  12. Rotolo, S.; Diotti, R.; Gordon, R.E.; Qiao, R.F.; Phelps, R.G.; Dong, J. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells. Int J Cancer. 115: 164-169; 2005. PMID: 15657897.
  13. Zhao, Y.; Zhang, Y.; Yang, Z.; Li, A.; Dong, J. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochem Biophys Res Commun. 370: 509-513; 2008. PMID: 18402768.
  14. Yang, Z.; Morrison, R.; Oates, C.; Sarria, J.; Patel, J.; Habibi, A.; Seyedjafari, R.; Hu, P.; Lennon, A.; Li, A.; Dong, J. HIV-1 Genotypic resistance testing on low viral load specimens using Abbott ViroSeq HIV-1 genotyping system. LabMedicine. 39: 671-672, 2008.
  15. Estrada, Y.; Dong, J.; Ossowski, L. MAPK signaling pathways in uPA-dependent cell migration of melanoma cells. Pigment Cell Melanoma Res. 22: 66-76; 2009. PMID: 18983537.
  16. Wang, Z.; Dong, J.; Eyzaguirre, E.J.; Tang, W.W.; Eltorky, M.A.; Qiu, S. Detection of human papilloma virus subtype 16 and P16 ink4a in invasive squamous cell carcinoma of the fallopian tube and concomitant squamous cell carcinoma in-situ of the cervix. J Obstet Gynaecol Res. 35: 385-389; 2009. PMID: 19708185.
  17. Murugan, A.K.; Dong, J.; Xie, J.; Xing, M. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle. 8: 2122–2124; 2009. PMID: 19411838.
  18. Patel, J.A.; Anderson, E.; Dong, J. False positive ultrasensitive HIV-1 bDNA viral load results in diagnosis of perinatal HIV-1 infection in the era of low transmission. LabMedicine. 40: 611-614; 2009.
  19. Li, J.; Xu, M.; Yang, Z.; Li, A.; Dong, J. Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. Cancer Invest. 28: 350-6; 2010. PMID: 19968499. (Citation Index 18, Journal Impact Factor 2.238, both accessed 3/3/2014).
  20. Li, Z.; Sheng, T.; Wan, X.; Li, T.; Wu, H.; Dong, J. Expression of HERV-K correlates with status of MEK-ERK and p16INK4A-CDK4 pathways in melanoma cells. Cancer Invest. 28:1031-7; 2010. PMID: 20874005.
  21. Clement, C.; Yang, Z.; Mayne, J.C.; Dong, J. HCV genotype and subtype distribution of patient samples tested at University of Texas Medical Branch in Galveston, Texas. J Mol Genetics. 2: 36-40; 2010.
  22. Xu, F.; Schwab, C.; Yang, X.; Weaver, S.; Li, A.; Sanborn, M.R.; Cloherty, G.A.; Dong, J. Low prevalence of non-subtype B HIV-1 strains in the Texas prisoner population. J Mol Genetics. 2: 41-44; 2010.
  23. Schlosshauer, P.W.; Deligdisch, L.; Penault-Llorca, F.; Fatemi, D.; Qiao, R.; Hao, S.; Yang, Z.; Sheng, T.; Pearl, M.; Dong, J. Loss of p16INK4A expression in low grade ovarian serous carcinomas. Int J Gynecol Pathol. 30: 22-29; 2011. PMID: 21131838.
  24. Murugan, A.K.; Dong, J.; Xing, M. Uncommon GNAQ, MMP8, AKT3, EGFR and PIK3R1 mutations in thyroid cancers. Endocr Pathol. 22: 97-102; 2011. PMID: 21487925.
  25. Hou, P.; Liu, D.; Dong, J.; Xing, M. The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle. 11: 286-295; 2012. PMID: 22189819.
  26. Fraase, K.; Hart, J.; Wu, H.; Ma, L.; Grant, F.; Li, A.; Lennon, A.; Hu, P.; Dong, J. BK virus as a potential co-factor for HPV in the development of cervical neoplasia. Ann Clin Lab Sci. 42 (2): 130-134; 2012. PMID: 22585607.
  27. Gulhati, P.; Zaytseva, Y.; Valentino, J.D.; Stevens, P.D.; Kim, J.T.; Sasazuki, T.; Shirasawa, S.; Lee, E.Y.; Weiss, H.L.; Dong, J.; Gao, T.; Evers, B.M. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PI3K3CA. Carcinogenesis 33 (9):1782-90, 2012. PMID: 22696593. (Citation Index 7, Journal Impact Factor 5.635, both accessed 3/3/2014).
  28. Esqueda, D.; Xu, F.; Moore, Y.; Yang, Z.; Huang, G.; Hu, P.C.; Dong, J. Lack of correlation between HERV-K expression and HIV-1 viral load in plasma specimens. Ann Clin Lab Sci. 43 (2): 122-125; 2013. PMID: 23694785.
  29. Huang, G.; Li Z.; Wan, X.; Wang, Y.; Dong, J. Human HERV-K encodes fusogenic activity in melanoma cells. J Carcinog. 12:5; 2013. PMID: 23599687. Featured in Global Medical Discovery [ISSN 1929-8536] (http://globalmedicaldiscovery.com).
  30. Wu, H.; Huang, G.; Romay-penabad, Z.; Pierangeli, S.; Dong, J. Do we need to worry about contamination by circulating fetal DNA? Clin Chem Lab Med. 52(5):e75-7; 2014. PMID: 24353144.
  31. Huang, G.; Krocker, J.D.; Kirk, J.L.; Wieck, L.R.; Merwat, S.N.; Soloway, R.D.; Ju, H.; Li, A.; Okorodudu, A.O.; Petersen, J.R.; Abdulla, N.E.; Duchini A.; Cicalese, L.; Rastellini, C.; Hu, P.C.; Dong, J. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clin Chem Lab Med. 52(6):899-909; 2014. PMID: 24406287.
  32. Kudose, S.; Dong, J. Clinical validation of quantitative BK real-time PCR assay for the detection and management of BKVN. Ann Clin Lab Sci. 44(4):455-60; 2014. PMID: 25361932.
  33. Tosur, M.; Geary, C.; Matalon, R.; Radhakrishnan, R.S.; Swischuk, L.E.; Tarry, W.; Dong, J.; Lee, P.D.K. Persistence of Müllerian Duct Structures in a Genetic Male with Distal Monosomy 10q. Am J Med Genet A. 167(4):791-6; 2015. PMID: 25820398.
  34. Dong, J.; Olano, J.P.; McBride, J.W.; Walker, D.H. Emerging pathogens: challenges and successes of molecular diagnostics. Journal of Molecular Diagnostics 10: 185-197; 2008. PMID: 18403608.
  35. Bechert, C.J.; Payne, D.; Schnadig, V.; Dong, J. BK associated nephropathy in renal transplant patients. American Journal of Clinical Pathology, 133:242-250, 2010. PMID: 20093233. (Citation Index 32, Journal Impact Factor 2.88, both accessed 3/3/2014 in Google Scholar).
  36. Hall, L.; Wilson, J.; Bernard, K.; Carbone, M.P.; Mubarak, H.S.E.; Hallam, S.E.; Klein, R.D.; Pancholi, P.; Schoonmaker, M.M.; Spector, E.B.; Vitazka, P.; Boonyaratanakornkit, J.; Bryant, B.; Dong, J.; Emmadi, R.; Furtado, M.R.; Lacbawan, F.; Martinez-Murillo, F.; Schutzbank, T.E.; Selvarangan, R.; Shyamala, V.; Williams, L.O.; Wu, A. CLSI MM19. Establishing molecular testing in clinical laboratory environments; Proposed Guideline. 2011.
  37. Jin, D.; Xie, S.; Mo, Z.; Liang, Y.; Guo, R.; Huang, G.; Dong, J. Circulating DNA – important biomarker of cancer. J Mol Biomark Diagn. 2012. doi: 10.4172/2155-9929.S2-009.
  38. Chen, B.; Dequeker, E.; Dong, J.; Emmadi, R.; Gordon, J.T.; Howell, R.M.; Killeen, A.; Levin, J.D.; Murray, C.N.; Pratt, V.M.; Rousseau, F.; Stockley, T.L.; Scheuner, M. CLSI MM20-P. Quality management for molecular genetic testing. 2012.
  39. Rincon, L.; Sedrak, M.P.; Sun, H., Gregorio, G., Kelly, B., Dong, J.  K type human endogenous retroviral elements in human melanoma. Advances in Genomics and Genetics, 4:153-159, 2014.
  40. Winn-Deen, E.S.; Zehnbauer, B.; Aisner, D.L.; Bijwaard, K.E.; Bromley, S.E.; Cankovic, C.; Deignan, J.L.; Dong, J.; Fehling, H.N.; Fernandes,H.; Gates, D.W.; Grinkemeyer, M.; Jackson, C.L.; Jessup, J.M.; Jewell, S.S.; Lefferts, J.A.; Roscoe, D.; Rothberg, P.G.; Schutzbank, T.E.; Sepulveda, A.R.; Sirko-Osadsa, D.A.; Vitazka, P.; Woolworth, J. Molecular diagnostic methods for solid tumors (nonhematological neoplasms); CLSI MM23. 2015.
  41. Sheila Govind, Clare Morris, Jason Hockley and the *Collaborative Study Group (Dong, J. group member). BK Virus (BKV) International Standard, WHO International Standard. The National Institute for Biological Standards and Control (NIBSC) 14-212. 2016.


clinical-laboratory-medicine-flyer Flyer